Eric Crombez - 01 Mar 2025 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Reporting relationship: EVP and Chief Medical Officer
Issuer ticker: RARE
Reported as of: 01 Mar 2025
Net transaction value: -$376,584
SEC form: 4
Accepted by SEC: 04 Mar 2025, 20:16:48 UTC
Prior SEC filing: 03 Feb 2025
Next SEC filing: 05 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Karah Parschauer, attorney-in-fact

Key filing fact

Eric Crombez filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 04 Mar 2025.

Key facts

This page summarizes Eric Crombez's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2025, 20:16.

Change

Previous filing in this sequence was filed on 03 Feb 2025.
Current net transaction value: -$376,584.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RARE transaction

Common Stock

Award

Transaction value: $0
Shares: +16,813
Change %: +35%
Price: $0.000000
Shares after: 65,244
Date: 01 Mar 2025
Ownership: Direct
Footnotes: F1

RARE transaction

Common Stock

Award

Transaction value: $0
Shares: +14,971
Change %: +23%
Price: $0.000000
Shares after: 80,215
Date: 01 Mar 2025
Ownership: Direct
Footnotes: F2

RARE transaction

Common Stock

Sale

Transaction value: $376,584
Shares: -8,945
Change %: -11%
Price: $42.10
Shares after: 71,922
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F3, F4, F5, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RARE transaction Derivative

Stock Ooption (Right to Buy)

Award

Transaction value: $0
Shares: +30,246
Change %
Price: $0.000000
Shares after: 30,246
Date: 01 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,246
Exercise price: $42.92
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

Footnote F2

Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.

Footnote F3

Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Footnote F6

Includes 652 shares acquired on April 30, 2024 and October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan

Footnote F7

On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.